COVID-19 pandemic and allergen immunotherapy-an EAACI survey.
COVID-19
SARS-CoV-2
allergen immunotherapy (AIT)
pandemic
survey
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
05
02
2021
received:
13
01
2021
accepted:
10
02
2021
pubmed:
4
3
2021
medline:
3
11
2021
entrez:
3
3
2021
Statut:
ppublish
Résumé
As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT. Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.
Sections du résumé
BACKGROUND
As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT.
METHODS
Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey
RESULTS
417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
CONCLUSIONS
This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.
Identifiants
pubmed: 33655519
doi: 10.1111/all.14793
pmc: PMC8013670
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3504-3516Informations de copyright
© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Int Arch Allergy Immunol. 2021;182(1):49-52
pubmed: 33059353
Allergy. 2021 Mar;76(3):689-697
pubmed: 32588922
J Allergy Clin Immunol Pract. 2020 May;8(5):1477-1488.e5
pubmed: 32224232
Allergy. 2018 Jun;73(6):1322-1330
pubmed: 29318637
Eur Urol Focus. 2020 Sep 15;6(5):1111-1119
pubmed: 32576530
J Allergy Clin Immunol. 2016 Jun;137(6):1887-1888
pubmed: 27090935
Allergy. 2021 Mar;76(3):648-676
pubmed: 32531110
Laryngorhinootologie. 2020 Oct;99(10):676-679
pubmed: 32823368
Pneumologie. 2021 Apr;75(4):284-292
pubmed: 33147639
J Neurol. 2020 Dec;267(12):3467-3475
pubmed: 32638107
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Allergy. 2020 Nov;75(11):2764-2774
pubmed: 32500526
Allergol Select. 2020 May 28;4:44-52
pubmed: 32568272
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Circ Heart Fail. 2020 Jun;13(6):e007274
pubmed: 32482087
Allergy. 2018 Apr;73(4):765-798
pubmed: 28940458
J Allergy Clin Immunol Pract. 2020 Jul - Aug;8(7):2135-2141
pubmed: 32426217
Allergy Asthma Immunol Res. 2020 Sep;12(5):783-791
pubmed: 32638559
Allergy. 2017 Aug;72(8):1156-1173
pubmed: 28152201
Allergy. 2019 Dec;74 Suppl 108:3-25
pubmed: 31872476
Allergy. 2020 Oct;75(10):2445-2476
pubmed: 32584441
Allergy. 2017 Nov;72(11):1597-1631
pubmed: 28493631
J Allergy Clin Immunol Pract. 2020 May;8(5):1489-1491
pubmed: 32220575
Ital J Pediatr. 2020 Jun 16;46(1):84
pubmed: 32546234
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Emerg Microbes Infect. 2020 Dec;9(1):1590-1599
pubmed: 32573350
Allergy. 2020 Oct;75(10):2503-2541
pubmed: 32535955
Allergy. 2018 Apr;73(4):739-743
pubmed: 29380390
Allergy. 2020 Jul;75(7):1699-1709
pubmed: 32196678
J Allergy Clin Immunol Pract. 2019 Mar;7(3):1017-1021
pubmed: 30385405
J Allergy Clin Immunol. 2020 Jul;146(1):227
pubmed: 32317114
Allergy. 2018 Apr;73(4):744-764
pubmed: 28748641
J Allergy Clin Immunol. 2015 Sep;136(3):556-68
pubmed: 26162571
Allergy. 2020 Jul;75(7):1546-1554
pubmed: 32329930
J Allergy Clin Immunol Pract. 2021 Feb;9(2):709-722.e2
pubmed: 33271350
Allergy. 2020 Feb;75(2):259-272
pubmed: 31230373
Ann Allergy Asthma Immunol. 2017 Dec;119(6):512-517
pubmed: 29103799
Allergy. 2020 Sep;75(9):2411-2414
pubmed: 32163594
J Allergy Clin Immunol Pract. 2020 Nov - Dec;8(10):3671-3672
pubmed: 32890757
Front Pediatr. 2020 Nov 23;8:565039
pubmed: 33330268
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
Allergo J Int. 2020;29(8):257-261
pubmed: 33312843
Allergo J Int. 2014;23(8):282-319
pubmed: 26120539
Clin Rheumatol. 2020 Nov;39(11):3205-3213
pubmed: 32996071
J Allergy Clin Immunol Pract. 2021 Jan;9(1):484-486
pubmed: 33039641
Pediatr Allergy Immunol. 2020 May;31 Suppl 25:1-101
pubmed: 32436290
Allergy. 2021 Mar;76(3):622-625
pubmed: 32589296
Allergy. 2015 Aug;70(8):897-909
pubmed: 25913519
Allergy. 2016 Mar;71(3):412-5
pubmed: 26228482
J Allergy Clin Immunol Pract. 2021 Jan;9(1):1-6.e1
pubmed: 33144147
Pediatr Allergy Immunol. 2017 Dec;28(8):728-745
pubmed: 28902467